EritreaTuberculosis profile
Population  2015 5.2 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.6 (0.28–1.1) 12 (5.3–20)
Mortality (HIV+TB only) 0.053 (0.018–0.11) 1 (0.34–2)
Incidence  (includes HIV+TB) 3.4 (1.6–5.9) 65 (30–113)
Incidence (HIV+TB only) 0.18 (0.085–0.32) 3.5 (1.6–6.1)
Incidence (MDR/RR-TB)** 0.14 (0–0.29) 2.7 (0–5.5)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.3 (0.12–0.49) 1.3 (0.31–2.2) 1.6 (0.42–2.7)
Males 0.33 (0.19–0.47) 1.5 (0.79–2.2) 1.8 (0.98–2.7)
Total 0.63 (0.4–0.86) 2.8 (1.6–4) 3.4 (1.6–5.9)
TB case notifications, 2015  
Total cases notified 2 094
Total new and relapse 2 060
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 65%
          - % bacteriologically confirmed among pulmonary 59%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 61% (35–130)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.22 (0.08–0.48)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 111 5%
          - on antiretroviral therapy 103 93%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  63
(9–120)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance   84% 135
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 32, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 32, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 91% 2 389
Previously treated cases, excluding relapse, registered in 2014 88% 34
HIV-positive TB cases, all types, registered in 2014 83% 128
MDR/RR-TB cases started on second-line treatment in 2013 83% 6
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
21% (19–23)
TB financing, 2016  
National TB budget (US$ millions) 4.2
Funding source: <1% domestic, 43% international, 57% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data